SSRI & SNRI Antidepressant Use During PreganancyEvidence links to Autism and ASD Related Injuries
SSRI and SNRI Antidepressant Use Increase Risk of Autism and ASD in Offspring
New evidence published in the Journal of the American Medical Association Pediatrics provides further confirmation of a link between antidepressant usage by mothers during pregnancy and the increased risk for autism and ASD-related injuries in maternal offspring. The list of relevant drugs includes is provided below. If you were prescribed one or more of these drugs while pregnant and have a child suffering from autism or a related injury, please CONTACT US by filling out the form below.
- Effexor®/Effexor XR®
The conclusions section from the abstract of the study is shown below and the article can be found here:
Conclusions and Relevance Use of antidepressants, specifically selective serotonin reuptake inhibitors, during the second and/or third trimester increases the risk of ASD in children, even after considering maternal depression. Further research is needed to specifically assess the risk of ASD associated with antidepressant types and dosages during pregnancy.
This study further builds on mounting evidence of the link between ASD and maternal antidepressant usage. Last year, a research paper published by scientists at the Johns Hopkins Bloomberg School of Public Health provided evidence of a connection between pregnant mothers use of certain type of medications, known as selective seratonin reuptake inhibitors or “SSRIs”, used in the treatment of depression, anxiety, and other medical conditions, and an increased risk for offspring with autism spectrum disorder or ASD. This study demonstrated that the greatest risk is associated with prenatal SSRI use during the first trimester of pregnancy, where the risk of having an autistic boy was nearly 3-times greater than for those mothers that were not given the medication.
Now there is evidence that these drugs may lead to an increased risk of ASD disorders in all three trimesters of fetal development.
We are now in the final stages of evaluating the evidence supporting filing lawsuits against the manufacturers of these drugs for failing to identify and warned these risks.